P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer

Objective: Calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types and grading.

Patients and methods:

100 cases of endometrial cancer will be included in the study, recruited from Alexandria university hospital gyne-oncology unit. Surgical staging, histopathological examination and immunohistochemistry of p53 were done to all cases to calculate the incidence of P53 immunohistochemistry abnormal staining in endometrial cancer and to identify its relation with disease stages, pathological types, grading.

Keywords: P53 immunohistochemistry, endometrial cancer, clinicopathological relation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Sex eligibility

Female

Study type

Observational

Primary location

Hossam Hassan El Sokkary

Alexandria, Egypt

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

endometrial cancer patients

Exclusion criteria

patients unfit for surgery

Treatment and study plan

p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Other

p 53 immunohistochemistry positive staining and relation to stages ,pathological types and grading

Primary outcomes

p53 immunohistochemistry

Time frame: 1 month

Incidence of abnormal staining of p53 in endometrial cancer
Relation of p53 abnormal staining with disease stages

Time frame: 1month

Relation of p53 abnormal staining with disease stages
Relation of p53 abnormal staining with disease pathological types

Time frame: 1 month

Relation of p53 abnormal staining with disease pathological types
Relation of p53 abnormal staining with disease pathological grades

Time frame: 1 month

Relation of p53 abnormal staining with disease pathological grades

Sponsors and collaborators

Lead sponsor

Hossam Hassan Aly Hassan El Sokkary

Other

Registry information

Official study title

P53 Immunohistochemistry Abnormal Staining in Endometrial Cancer and Its Relation With Disease Stages, Pathological Types and Grading

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: Sep 16, 2022
Registry last updated: Sep 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed